Sponsor or institution

Clinical trials and research at Sanofi

• 83Clinical trials
• 1New in 30 days
• 71Countries

Newest trials

All recruiting trials (83)

• Tolebrutinib in real-world MS care for patients treated by clinicians

  This real-world study sees how tolebrutinib is used for multiple sclerosis patients and what outcomes look like in everyday practice.

  Recruiting Sanofi · Marina, Abu Dhabi Emirate · NCT07898371

• Omicron-based COVID-19 vaccine with Matrix-M given as a single dose in older adults and high-risk individuals

  A single-dose Omicron-subvariant vaccine with Matrix-M is tested to see if it is safe and can induce an immune response in adults 65+ and in younger adults with conditions that raise the risk of severe COVID-19, who were previously vaccinated.

  Recruiting at 20 sites Phase 4 Sanofi · Fair Oaks, California and 19 other locations · NCT07861542

• Rilzabrutinib in adults with severe kidney impairment vs. normal kidney function

  This study tests how rilzabrutinib behaves in the body and its safety in adults with severe kidney impairment compared to healthy adults.

  Recruiting Phase 1 Sanofi · Hialeah, Florida · NCT07853131

• Duvakitug in adults with moderate to severe hidradenitis suppurativa

  This study tests different doses of duvakitug to see if it helps adults with moderate to severe hidradenitis suppurativa compared with placebo.

  Recruiting at 4 sites Phase 2 Sanofi · Birmingham, Alabama and 3 other locations · NCT07812116

• RSV+HMPV protein shot for adults 60 and older

  A single shot of a two-virus vaccine is being tested in adults 60+ to see if it can prevent RSV and hMPV infections compared with placebo.

  Recruiting at 21 sites Phase 2 Sanofi · Bruse, Australian Capital Territory and 20 other locations · NCT07810010

• Egg-based H5N8 influenza vaccine at multiple doses with or without adjuvant in healthy adults

  This trial tests whether an egg-based H5N8 flu vaccine, given at low to high doses with or without an adjuvant, is safe and can provoke a stronger immune response in healthy adults 18 and older.

  Recruiting at 16 sites Phase 1/2 Sanofi · Tempe, Arizona and 15 other locations · NCT07779408

• Belumosudil vs Best Available Therapy for chronic graft-versus-host disease

  In people aged 12 and up with chronic graft-versus-host disease, the study tests belumosudil to see if it works better than the doctor’s choice of best available therapy after prior treatments have failed.

  Recruiting at 3 sites Phase 3 Sanofi · Amsterdam and 2 other locations · NCT07771439

• RSV+HMPV vaccine candidate in adults aged 60 and older

  A vaccine candidate for RSV and HMPV will be tested in adults 60+ to see if it safely provokes an immune response and how it compares to placebo.

  Recruiting at 50 sites Phase 1/2 Sanofi · Gadsden, Alabama and 49 other locations · NCT07734649

• Is its immune response and safety in babies and toddlers when given a meningococcal vaccine in China

  This study tests whether the MenACYW conjugate vaccine safely produces an immune response in healthy infants and toddlers in China, compared with locally licensed vaccines.

  Recruiting at 8 sites Phase 3 Sanofi · Huanggang and 7 other locations · NCT07710872

• IV sarilumab for adults with rheumatoid arthritis

  This study tests IV sarilumab to see how it works and how safe it is for adults with moderately to severely active rheumatoid arthritis, with or without certain standard arthritis medicines.

  Recruiting at 12 sites Phase 1/2 Sanofi · Centennial, Colorado and 11 other locations · NCT07704580

• Dose-Optimization/Expansion of SAR445877 in adults with advanced gastric or GEJ cancer

  This phase 2 study tests SAR445877 as a single-drug treatment to see if it helps adults in China with advanced gastric or GEJ cancer after at least one prior therapy.

  Recruiting Phase 2 Sanofi · Shanghai · NCT07692204

• A daily pill test of SAR448851 for early Alzheimer’s disease

  This study tests whether taking SAR448851 by mouth once daily can help people with early Alzheimer’s disease compare to a placebo.

  Recruiting at 32 sites Phase 2 Sanofi · Long Beach, California and 31 other locations · NCT07688213

• First-in-human study of SAR447971

  This study tests SAR447971 against placebo in healthy adults and in people with hidradenitis suppurativa to see how the drug behaves and whether it is safe.

  Recruiting Phase 1 Sanofi · Leiden · NCT07629336

• Post‑marketing safety check of MenQuadfi in children and adults in Korea

  This real‑world surveillance in Korea tests MenQuadfi for safety in people from 6 weeks to 55 years old who are receiving it for the first time.

  Recruiting at 9 sites Sanofi · Busan and 8 other locations · NCT07621653

• Dupilumab in COPD: Real-world Registry of Outcomes

  This registry tests how dupilumab works for COPD patients in everyday care and whether it lowers flare-ups and improves lung function and quality of life.

  Recruiting at 7 sites Sanofi · Indianapolis, Indiana and 6 other locations · NCT07612878

• Understanding asthma characteristics and outcomes in routine care

  This project will collect information and follow people with asthma to see how symptoms, treatments, biomarkers, and quality of life change over time, especially among those using inhaled corticosteroids.

  Recruiting at 25 sites Sanofi · Bessemer, Alabama and 82 other locations · NCT07556159

• Different vaccine formulations for RSV or H5 flu in adults 18–49

  This trial will try several vaccine formulations that produce either the RSV antigen or the H5 flu antigen in healthy adults 18 to 49 to see if they are safe and trigger immune responses.

  Recruiting at 6 sites Phase 1 Sanofi · Griffith, Queensland and 5 other locations · NCT07516418

• Dupilumab's effect on anxiety and depression in moderate-to-severe atopic dermatitis

  This project will see if dupilumab reduces anxiety and depression in people with moderate-to-severe atopic dermatitis who are starting or recently started the medicine.

  Recruiting at 4 sites Sanofi · Doha and 6 other locations · NCT07467564

• Real-world outcomes for people with Type 1 diabetes treated with teplizumab through managed access programs

  This project will look at health records to see how teplizumab is being used and how people's Type 1 diabetes progressed after receiving it through managed access programs.

  Recruiting at 2 sites Sanofi · Leuven and 15 other locations · NCT07457580

• Frexalimab versus tacrolimus to prevent kidney transplant rejection

  This trial will test whether frexalimab injections given for up to five years work as well and are as safe as tacrolimus capsules at preventing rejection in adults getting their first kidney transplant who have low-to-moderate immune risk.

  Recruiting at 73 sites Phase 2/3 Sanofi · San Francisco, California and 72 other locations · NCT07412470

• Long-term follow-up of dupilumab treatment for COPD

  This project will follow adults with uncontrolled COPD and high blood eosinophils who start dupilumab in routine care to see if it is safe and improves symptoms and quality of life over 36 months.

  Recruiting at 28 sites Sanofi · Aix-en-Provence and 27 other locations · NCT07380711

• Long-term outcomes of teplizumab in routine care

  This project will see if teplizumab given to people with Stage 2 Type 1 Diabetes delays the start of Stage 3 diabetes and how it affects their quality of life over time.

  Recruiting at 12 sites Sanofi · Washington D.C., District of Columbia and 11 other locations · NCT07360080

• Comparing three production lots of a 21‑valent pneumococcal vaccine in infants

  This trial will test if three different production lots of a 21‑valent pneumococcal vaccine give similar immune responses and are as safe as the licensed 20‑valent vaccine when given to infants starting at about 2 months of age.

  Recruiting at 25 sites Phase 3 Sanofi · Fayetteville, Arkansas and 24 other locations · NCT07348692

• Comparing under-the-skin versus intravenous frexalimab for adults with multiple sclerosis

  This will test whether subcutaneous frexalimab given every 4 weeks works as well as intravenous frexalimab every 4 weeks for adults with relapsing MS or non-relapsing secondary progressive MS.

  Recruiting at 68 sites Phase 3 Sanofi · Cullman, Alabama and 67 other locations · NCT07325292

• Tracking teens and adults with atopic dermatitis who start or change systemic treatment

  This registry will follow people aged 12 and up with atopic dermatitis who start or switch systemic treatments to see how well the treatments work and how safe they are in everyday care.

  Recruiting at 81 sites Sanofi · Birmingham, Alabama and 81 other locations · NCT07290803

• Sarilumab for early polymyalgia rheumatica in adults

  This study tests whether sarilumab given every two weeks, with a prednisone taper, helps people with early polymyalgia rheumatica more than placebo plus prednisone taper.

  Recruiting at 85 sites Phase 3 Sanofi · Avondale, Arizona and 84 other locations · NCT07286214

• Fitusiran prophylaxis for boys aged 1 to under 12 with severe hemophilia A or B

  This study tests whether fitusiran given as prophylaxis can reduce bleeding in boys aged 1 to under 12 with severe hemophilia A or B, with or without inhibitors.

  Recruiting at 37 sites Phase 3 Sanofi · Los Angeles, California and 36 other locations · NCT07285460

• Post-market safety check of Efluelda in older adults after a flu vaccination

  This study tests whether Efluelda is safe for adults aged 65 and older when used in routine clinical care after it has been marketed.

  Recruiting at 15 sites Sanofi · Goyang-si, Gyeonggi-do and 14 other locations · NCT07282795

• Real-world comparison of experiences for people with stage 2 type 1 diabetes who did or did not receive teplizumab

  This study will compare real-world experiences, quality of life, and disease progression for people aged 8 and older with stage 2 type 1 diabetes who received teplizumab versus similar people who did not.

  Recruiting Sanofi · San Francisco, California · NCT07260110

• Single-dose 21-valent pneumococcal conjugate vaccine for children and teens with sickle cell disease

  This trial tests whether a single dose of the new PCV21 vaccine is safe and helps children and teens (ages 2–17) with sickle cell disease make protective antibodies compared with the licensed 20-valent pneumococcal vaccine.

  Recruiting at 7 sites Phase 3 Sanofi · Atlanta, Georgia and 6 other locations · NCT07247188

• SAR445399 treatment for adults with moderate to severe hidradenitis suppurativa

  This will test two doses of SAR445399 versus placebo in adults with moderate to severe hidradenitis suppurativa to see if it reduces abscesses and inflammatory nodules and is safe.

  Recruiting at 85 sites Phase 2 Sanofi · Scottsdale, Arizona and 85 other locations · NCT07225569

• One-time intravitreal SAR446597 injection for geographic atrophy due to AMD

  This trial will try a single eye injection of SAR446597 to slow geographic atrophy in people 60 and older with AMD.

  Recruiting at 35 sites Phase 1/2 Sanofi · Peoria, Arizona and 34 other locations · NCT07215234

• Real-world safety monitoring of Beyfortus (nirsevimab) in Korean infants and toddlers

  This program follows children up to 24 months in Korea who receive Beyfortus to see if the medicine is safe when used in routine care.

  Recruiting Sanofi · Hwaseong-si, Gyeonggi-do · NCT07200206

• Lunsekimig versus placebo for eosinophilic COPD

  This trial tests whether subcutaneous lunsekimig can help adults 40–80 with inadequately controlled COPD who have a high blood eosinophil count.

  Recruiting at 310 sites Phase 3 Sanofi · Birmingham, Alabama and 313 other locations · NCT07190222

• Lunsekimig versus placebo for inadequately controlled eosinophilic COPD

  This study tests whether regular subcutaneous lunsekimig helps adults aged 40–80 with eosinophilic COPD that remains uncontrolled despite triple inhaled therapy.

  Recruiting at 312 sites Phase 3 Sanofi · Chandler, Arizona and 313 other locations · NCT07190209

• Rilzabrutinib versus placebo for adults with IgG4-related disease (52-week treatment)

  This 52-week study will try rilzabrutinib tablets to see if they prevent disease flares and better control symptoms in adults with active IgG4-related disease compared with placebo.

  Recruiting at 91 sites Phase 3 Sanofi · Fontana, California and 94 other locations · NCT07190196

• Duvakitug maintenance treatment for moderate-to-severe ulcerative colitis

  This trial tests whether duvakitug can help keep adults with moderately to severely active ulcerative colitis in clinical response after a successful induction treatment.

  Recruiting at 171 sites Phase 3 Sanofi · Tucson, Arizona and 170 other locations · NCT07185009

• Duvakitug to induce remission in moderate to severe ulcerative colitis

  This 12-week treatment will test whether duvakitug helps adults (and some older teens) with moderately to severely active ulcerative colitis get into remission and feel better.

  Recruiting at 239 sites Phase 3 Sanofi · Peoria, Arizona and 239 other locations · NCT07184996

• Duvakitug maintenance treatment for moderately to severely active Crohn's disease.

  We will test whether duvakitug can keep symptoms controlled in adults with moderately to severely active Crohn's disease who responded to initial treatment.

  Recruiting at 109 sites Phase 3 Sanofi · Colorado Springs, Colorado and 108 other locations · NCT07184944

• Induction treatment with duvakitug for moderate to severe Crohn's disease

  This trial will test whether duvakitug helps adults with moderate to severe Crohn's disease improve symptoms over a 12-week induction period compared with placebo.

  Recruiting at 461 sites Phase 3 Sanofi · Peoria, Arizona and 460 other locations · NCT07184931

• Brivekimig for moderate to severe hidradenitis suppurativa

  This trial will test whether brivekimig can reduce symptoms in people with moderate to severe hidradenitis suppurativa.

  Recruiting at 77 sites Phase 2 Sanofi · Phoenix, Arizona and 84 other locations · NCT07170917

• SAR444336 to help adults with microscopic colitis stay in remission while on budesonide.

  This will test whether adding SAR444336 to budesonide helps adults with microscopic colitis who are in remission stay symptom-free longer than placebo.

  Recruiting at 22 sites Phase 2 Sanofi · Leuven and 23 other locations · NCT07156175

• Belumosudil treatment for children with chronic graft-versus-host disease (schoolROCK)

  This trial will test whether the oral drug belumosudil helps children ages 1 to under 18 with moderate-to-severe chronic graft-versus-host disease that has not improved after at least two prior systemic treatments.

  Recruiting at 35 sites Phase 2 Sanofi · Los Angeles, California and 34 other locations · NCT07116031

• Teplizumab versus placebo for recent-onset Stage 3 Type 1 diabetes in people aged 1–25

  This will test whether an IV course of teplizumab can improve blood sugar control and reduce the need for mealtime insulin over one year in people aged 1–25 who were recently diagnosed with stage 3 type 1 diabetes.

  Recruiting at 202 sites Phase 3 Sanofi · Scottsdale, Arizona and 201 other locations · NCT07088068

• Oral rilzabrutinib versus placebo for adults with warm autoimmune hemolytic anemia

  This trial tests whether the oral drug rilzabrutinib can raise and sustain hemoglobin better than placebo in adults with primary warm autoimmune hemolytic anemia who have not had lasting benefit from steroids.

  Recruiting at 105 sites Phase 3 Sanofi · Phoenix, Arizona and 104 other locations · NCT07086976

• Dupilumab injections to reduce airway inflammation in adults 40–85 with COPD

  This trial will test whether dupilumab injections can reduce airway inflammation and mucus plugging and improve breathing, exacerbations, and quality of life in people aged 40–85 with moderate-to-severe COPD and evidence of type 2 inflammation.

  Recruiting at 84 sites Phase 4 Sanofi · Birmingham, Alabama and 84 other locations · NCT07053423

• Dupilumab for adults with COPD and high blood eosinophils in routine care

  This study will try dupilumab in adults with uncontrolled COPD and high blood eosinophils to see if it improves symptoms, quality of life, and safety over 24 months in routine care.

  Recruiting at 18 sites Sanofi · Auerbach and 17 other locations · NCT07052396

• Early detection of Type 1 diabetes in children and adolescents who have a parent or sibling with Type 1 diabetes

  This project will test a screening process to find pre-symptomatic Type 1 diabetes in kids and teens who have a first-degree relative with Type 1 diabetes.

  Recruiting at 7 sites Sanofi · Kuwait City, Al Asimah / Capital Governorate and 6 other locations · NCT07038473

• Acne mRNA vaccine for adults with mild facial acne

  This trial will test two injections of an acne mRNA vaccine versus placebo in adults 18–45 with mild facial acne to see if it's safe, triggers an immune response, and improves acne.

  Recruiting at 4 sites Phase 1/2 Sanofi · Encino, California and 3 other locations · NCT07013747

• Oral rilzabrutinib for adults with immune thrombocytopenia after first-line treatment fails.

  This study will test whether the oral drug rilzabrutinib can raise and keep platelet counts up in adults with ITP who did not have lasting benefit from first-line therapy.

  Recruiting at 36 sites Phase 3 Sanofi · Clovis, California and 35 other locations · NCT07007962

• Rilzabrutinib treatment for adults with Graves' disease

  This trial will test two doses of the oral drug rilzabrutinib in adults with Graves' disease, with or without Graves' orbitopathy, to see which dose better controls hyperthyroidism and is safe.

  Recruiting at 19 sites Phase 2 Sanofi · Buenos Aires and 23 other locations · NCT06984627

• Evaluating Rilzabrutinib for Sickle Cell Disease in Patients Aged 10 to 65

  This study is testing a new medication called rilzabrutinib to see if it can help people aged 10 to 65 with sickle cell disease have fewer pain crises and improve their overall health.

  Recruiting at 63 sites Phase 3 Sanofi · Birmingham, Alabama and 62 other locations · NCT06975865

• Treatment outcomes for people with chronic inflammatory demyelinating polyneuropathy (CIDP)

  See if current CIDP treatments are helping people who still have nerve weakness or disability after at least three months on standard therapy.

  Recruiting Sanofi · Swiftwater, Pennsylvania · NCT06968975

• SAR442970 treatment for moderate-to-severe Crohn's disease.

  This trial will test whether two different doses of SAR442970 work better than placebo for people with moderate-to-severe Crohn's disease who have not had an adequate response or cannot tolerate standard or advanced therapies.

  Recruiting at 75 sites Phase 2 Sanofi · Fairhope, Alabama and 77 other locations · NCT06958536

• Weekly efanesoctocog alfa for hemophilia A with joint synovial hypertrophy

  This trial tests whether taking efanesoctocog alfa once a week for 12 months can reduce synovial hypertrophy in people aged 12 and older with moderate to severe hemophilia A.

  Recruiting at 13 sites Phase 4 Sanofi · Los Angeles, California and 18 other locations · NCT06941870

• Chlamydia mRNA vaccine for young adults

  This study is testing a new Chlamydia mRNA vaccine in young adults aged 18 to 29 to see if it is safe and effective.

  Recruiting at 7 sites Phase 1 Sanofi · Bruce, Australian Capital Territory and 6 other locations · NCT06891417

• SAR446268 gene therapy for non-congenital myotonic dystrophy type 1

  This will try a single intravenous dose of SAR446268 gene therapy to lower toxic DMPK mRNA and improve muscle function in people aged 10 to 55 with non‑congenital myotonic dystrophy type 1.

  Recruiting at 10 sites Phase 1/2 Sanofi · Gainesville, Florida and 9 other locations · NCT06844214

• Long-term assessment of dupilumab for eosinophilic esophagitis in Germany

  This study is testing how well dupilumab works and how safe it is for people aged 12 and older with eosinophilic esophagitis in Germany over two years.

  Recruiting at 15 sites Sanofi · Aschaffenburg, Bavaria and 14 other locations · NCT06695897

• Evaluating iGlarLixi for managing Type 2 Diabetes in Chinese patients

  This study is testing whether a new diabetes treatment called iGlarLixi can help Chinese patients with Type 2 Diabetes better control their blood sugar compared to a standard medication.

  Recruiting Phase 4 Sanofi · Beijing · NCT06671587

• Avalglucosidase alfa treatment for children with Pompe disease

  This study is testing a new treatment called avalglucosidase alfa to see if it helps children with infantile-onset Pompe disease feel better over a year.

  Recruiting Phase 4 Sanofi · Shanghai · NCT06666413

• Evaluating DR-0201 for autoimmune diseases

  This study is testing a new drug called DR-0201 to see if it can help people with autoimmune diseases like lupus and Sjogren's syndrome feel better and how safe it is.

  Recruiting at 8 sites Phase 1 Sanofi · Melbourne, Victoria and 7 other locations · NCT06647069

• Investigating SAR446523 for treating relapsed/refractory myeloma

  This study is testing a new treatment called SAR446523 for adults with relapsed or refractory multiple myeloma to see how well it works and find the best dose to use.

  Recruiting at 19 sites Phase 1 Sanofi · Phoenix, Arizona and 18 other locations · NCT06630806

• Evaluating treatments for kidney diseases in young to middle-aged adults

  This study is testing three different treatments for kidney diseases in young to middle-aged adults to see if they can reduce protein levels in urine and help with symptoms over 24 weeks.

  Recruiting at 78 sites Phase 2 Sanofi · Birmingham, Alabama and 78 other locations · NCT06500702

• Registry for patients with Stage 2 Type 1 Diabetes

  This study is looking to see how well the treatment TZIELD can help people with Stage 2 Type 1 Diabetes by tracking their health over time compared to those who aren't using the treatment.

  Recruiting at 37 sites Sanofi · Los Angeles, California and 36 other locations · NCT06481904

• Evaluating DR-0201 for patients with relapsed B-cell Non-Hodgkin Lymphoma

  This study is testing a new treatment called DR-0201 to see if it can help adults with relapsed B-cell non-Hodgkin lymphoma who have already tried other therapies.

  Recruiting at 15 sites Phase 1 Sanofi · Camperdown, New South Wales and 15 other locations · NCT06392477

• Evaluating an mRNA vaccine for treating moderate to severe acne

  This study is testing a new mRNA vaccine to see if it can safely help adults aged 18 to 45 with moderate to severe acne.

  Recruiting at 94 sites Phase 1/2 Sanofi · Scottsdale, Arizona and 93 other locations · NCT06316297

• Investigating Dupilumab for Children with Prurigo Nodularis

  This study is testing if Dupilumab can help children with prurigo nodularis feel better and stay safe while using the medication.

  Recruiting at 15 sites Phase 3 Sanofi · Palo Alto, California and 14 other locations · NCT06293053

• Testing riliprubart for treating chronic inflammatory demyelinating polyneuropathy

  This study is testing if a new treatment called riliprubart can work better than the usual IVIg treatment for adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

  Recruiting at 129 sites Phase 3 Sanofi · Homewood, Alabama and 133 other locations · NCT06290141

• Long-term safety and immune response of olipudase alfa in young children with acid sphingomyelinase deficiency

  This study is testing the long-term safety and immune response of a treatment called olipudase alfa in young children under 2 years old who have acid sphingomyelinase deficiency.

  Recruiting at 6 sites Sanofi · Chicago, Illinois and 5 other locations · NCT06192576

• Observing how adolescents with severe atopic dermatitis respond to dupilumab treatment

  This study looks at how well dupilumab treatment works for teenagers aged 12 to 17 with severe eczema over a year, focusing on their symptoms and quality of life.

  Recruiting at 9 sites Sanofi · Bologna and 8 other locations · NCT06192563

• Testing fitusiran to prevent bleeds in severe hemophilia A patients switching from emicizumab

  This study is testing if fitusiran can help prevent bleeding in men with severe hemophilia A who are switching from another treatment called emicizumab.

  Recruiting at 3 sites Phase 4 Sanofi · Los Angeles, California and 2 other locations · NCT06145373

• Testing the effectiveness of belumosudil for treating lung transplant rejection

  This study is testing if belumosudil can help improve lung function in adults who have had a lung transplant and are experiencing ongoing issues with their new lungs.

  Recruiting at 81 sites Phase 3 Sanofi · Birmingham, Alabama and 84 other locations · NCT06082037

• Safety study of avalglucosidase alfa during pregnancy

  This study is looking at how safe the drug avalglucosidase alfa is for pregnant women and their babies during pregnancy and breastfeeding.

  Recruiting Sanofi · Bridgewater, New Jersey · NCT05734521

• Testing SAR445877 for advanced solid tumors

  This study is testing a new cancer treatment called SAR445877 to see if it can help adults with advanced solid tumors feel better and improve their health, both on its own and with other cancer therapies.

  Recruiting at 21 sites Phase 1/2 Sanofi · Newark, Delaware and 21 other locations · NCT05584670

• Treatment of chronic itching with dupilumab

  This study is testing if a medication called dupilumab can help adults with severe chronic itching feel better.

  Recruiting at 81 sites Phase 3 Sanofi · Bakersfield, California and 93 other locations · NCT05263206

• Monitoring outcomes of women and their babies after MenQuadfi® vaccination during pregnancy

  This study is looking at the health of pregnant women and their babies after they receive the MenQuadfi® vaccine to see if there are any effects from the vaccination.

  Recruiting Sanofi · Swiftwater, Pennsylvania · NCT04843111

• Combining Isatuximab with New Treatments for Refractory Plasma Cell Myeloma

  This study is testing a new combination of isatuximab with other treatments to see if it helps people with tough-to-treat plasma cell myeloma feel better.

  Recruiting at 24 sites Phase 1/2 Sanofi · Atlanta, Georgia and 24 other locations · NCT04643002

• Registry for pregnant women vaccinated with Dengvaxia

  This study is tracking the health of pregnant women and their babies who received the Dengvaxia vaccine to see how it affects their pregnancies and infant development.

  Recruiting Sanofi · San Juan · NCT04486638

• Finding the right dose of sarilumab for children with systemic juvenile idiopathic arthritis

  This study is testing the right dose of sarilumab to see how well it works and how safe it is for children and teens with systemic juvenile idiopathic arthritis.

  Recruiting at 33 sites Phase 2 Sanofi · San Miguel de Tucumán, Tucumán Province and 39 other locations · NCT02991469

• Tracking pregnancy outcomes in women with Pompe disease

  This study looks at the pregnancy experiences and outcomes for women with Pompe disease to see how it affects both them and their babies.

  Recruiting at 34 sites Sanofi · Phoenix, Arizona and 34 other locations · NCT00567073

• Registry tracking outcomes for patients with Gaucher disease

  This study tracks the health and progress of people with Gaucher disease to help improve treatment and care for them, including those who are pregnant.

  Recruiting at 238 sites Sanofi · Phoenix, Arizona and 316 other locations · NCT00358943

• Global registry for tracking Pompe disease outcomes

  This study is tracking the health and progress of people with Pompe disease to learn more about how it affects them and to see how well treatments are working.

  Recruiting at 207 sites Sanofi · Birmingham, Alabama and 281 other locations · NCT00231400

• Registry for tracking Fabry disease and pregnancy outcomes

  This study is tracking the health of pregnant women with Fabry disease to see how pregnancy affects them and their babies.

  Recruiting at 228 sites Sanofi · Birmingham, Alabama and 283 other locations · NCT00196742

Quick answers

How many clinical trials run by Sanofi are recruiting right now?

83, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 71 countries. The most sites are in United States (53 trials), Germany (35 trials), Italy (33 trials), Canada (31 trials), Spain (31 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 22, Phase 2: 12, Phase 1/2: 9, Phase 1: 7. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →